METHOD OF TREATING LATENT SUBRETINAL NEOVASCULAR MEMBRANES Russian patent published in 2010 - IPC A61N5/67 A61K39/395 A61K31/409 A61P27/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, ophthalmology, and can be used for treating latent subretinal neovascular membranes. That is ensured by introduction of the vascular endothelial growth factor inhibitor ranibizumab in dosage 0.3-0.5 mg transsclerally in the posterior vitreous body. In 5-7 days after reduction of neovessel permeability and tissue oedema, a neovascular membrane is sized by fluorescent angiography. Further, the photosensitiser Verteporfin 0.08-0.1 mg/kg is administered. In 15 min, the neovessels within SNM borders are exposed to a diode laser of wave length 689 nm at power density 500-600 mWt/cm² for 83-100 seconds in total dosage to 50 J/cm².

EFFECT: method allows improving visual functions, reducing retinal damages, lowering possibility of recurrent neovascularisation, improving life quality in the rehabilitation period.

2 ex